Mostrar el registro sencillo del ítem
dc.contributor.author | Brown, B. | |
dc.contributor.author | Blas Blas, Magaly Marlitz | |
dc.contributor.author | Cabral, A. | |
dc.contributor.author | Cárcamo Cavagnaro, César Paul Eugenio | |
dc.contributor.author | Gravitt, P. | |
dc.contributor.author | Halsey, N. | |
dc.date.accessioned | 2022-01-18T19:26:48Z | |
dc.date.available | 2022-01-18T19:26:48Z | |
dc.date.issued | 2012 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12866/10894 | |
dc.description.abstract | Two hundred female sex workers (FSWs) in Lima, Peru were randomized to receive HPV4 vaccine in the standard (0, 2, 6 months) or a modified schedule (0, 3, 6 months). One hundred and eighty four (92%) participants completed 3 doses of vaccine. Baseline seropositive rates were 58% for HPV6, 22.5% for HPV11, 41.5% for HPV16, and 13% for HPV18. The final geometric mean antibody titer (GMT) following vaccination was significantly greater for women who were seropositive at baseline compared to seronegative women: HPV6 (GMT ratio = 2.3, p< 0.01), HPV11 (GMT ratio = 2.7, p< 0.01), HPV16 (GMT ratio = 1.3, p= 0.04), and HPV18 (GMT ratio = 2.4, p< 0.01). Antibody titers in the modified schedule were not inferior to those in the standard schedule, suggesting the modified schedule may be paired with required STD visits. Although all women benefit from vaccination, administration at a younger age and before sexual debut is needed to achieve maximum protection from vaccine. | en_US |
dc.language.iso | eng | |
dc.publisher | Elsevier | |
dc.relation.ispartofseries | Vaccine | |
dc.rights | info:eu-repo/semantics/restrictedAccess | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es | |
dc.subject | Humans | en_US |
dc.subject | Peru | en_US |
dc.subject | article | en_US |
dc.subject | controlled study | en_US |
dc.subject | major clinical study | en_US |
dc.subject | priority journal | en_US |
dc.subject | sexual behavior | en_US |
dc.subject | prostitution | en_US |
dc.subject | Sex Workers | en_US |
dc.subject | Treatment Outcome | en_US |
dc.subject | randomized controlled trial | en_US |
dc.subject | antibody response | en_US |
dc.subject | antibody titer | en_US |
dc.subject | Vaccination | en_US |
dc.subject | groups by age | en_US |
dc.subject | absence of side effects | en_US |
dc.subject | drug response | en_US |
dc.subject | condyloma acuminatum | en_US |
dc.subject | Human papillomavirus type 11 | en_US |
dc.subject | Human papillomavirus type 16 | en_US |
dc.subject | Human papillomavirus type 18 | en_US |
dc.subject | Human papillomavirus type 6 | en_US |
dc.subject | Papillomavirus Infections | en_US |
dc.subject | Papillomavirus Vaccines | en_US |
dc.subject | Wart virus vaccine | en_US |
dc.subject | uterine cervix cancer | en_US |
dc.subject | drug withdrawal | en_US |
dc.subject | Immune response | en_US |
dc.subject | Antibodies, Viral | en_US |
dc.subject | HPV vaccine | en_US |
dc.subject | Female sex workers | en_US |
dc.subject | Human papillomavirus | en_US |
dc.subject | virus DNA | en_US |
dc.subject | Alphapapillomavirus | en_US |
dc.subject | Adherence | en_US |
dc.subject | virus antibody | en_US |
dc.subject | cancer immunization | en_US |
dc.subject | Cervix Uteri | en_US |
dc.subject | Gammapapillomavirus | en_US |
dc.subject | Immunization Schedule | en_US |
dc.subject | virus immunity | en_US |
dc.title | Randomized trial of HPV4 vaccine assessing the response to HPV4 vaccine in two schedules among Peruvian female sex workers | en_US |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | https://doi.org/10.1016/j.vaccine.2012.01.058 | |
dc.subject.ocde | https://purl.org/pe-repo/ocde/ford#3.01.00 | |
dc.relation.issn | 1873-2518 |
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |